KRIBIOLISA Sunitinib Malate (SUTENT) ELISA

Enzyme Immunoassay for the quantitative determination of Sunitinib in serum, plasma and cell culture supernatant Sunitinib (SUTENT) is a medication used to treat cancer. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib Malate is an antineoplastic agent, Flk-1 inhibitor, and ATP-competitive inhibitor of PDGFRβ. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The KRIBIOLISA™ Sunitinib ELISA is a competitive inhibition immunoassay for the determination of Sunitinib. The microplate is coated with VEGFA protein. VEGFA protein is a known dimeric glycoprotein which functions as a ligand for the receptor VEGFR2 (Flk1). Samples and standards containing Sunitinib is added to the plate with HRP conjugated VEGFR-2 from the kit simultaneously. The Sunitinib in the samples and standard will inhibit the binding of VEGFR-2 to the microplate. The amount of Sunitinib is inversely proportional to the color developed in the microplate post addition of TMB substrate and stopping the reaction. The absorbance is read at 450 nm.